Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.

Seer, Inc.

SEERNASDAQ
Wall Street Score · overall investment32/100
$2.04USD+$0.05 (+2.51%)
Company website seer.bio
Headquarters3800 Bridge Parkway, Redwood City, CA, 94065, US
Financial statement currencyUSD · no FX conversion applied
Healthcare · Biotechnology
Price updated todayFinancials updated Oct 19, 2026

SEER · Price history

Price at last available close

$2.00

−$0.15 (-6.98%) 1M

2026-10-29

Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.

Company & revenue

About Seer, Inc.

Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.

Who they are

Seer, Inc. is a life sciences firm specializing in developing and commercializing advanced technologies designed to unravel the complexities of the proteome. At the core of its offerings is the Proteograph Product Suite, an integrated platform comprising specialized consumables, automated instrumentation, and sophisticated software. This comprehensive solution empowers researchers to conduct advanced proteomic studies across various applications, including therapeutic and diagnostic investigations, as well as clinical trials.

How they make money

Seer generates revenue primarily through the sale of its Proteograph product suite, which includes proprietary consumables, automation instruments, and software. The company also derives revenue from service arrangements, including maintenance, support, and professional services provided to research and clinical customers.

Products & services

The Proteograph Product Suite is an integrated solution for proteomics, featuring the SP200 Automation Instrument, Proteograph ONE Assay, and associated software for unbiased, peptide-level protein detection.

Brands & revenue mix

Proteograph

The core product suite brand encompassing instruments, assays, and software.

Separate brand revenue is not available in this research.Source

Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.

Product / operating segments

No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.

Geographic revenue

No reconciled geographic revenue breakdown was confirmed for the current research period.

Customer types

  • Academic research institutionsSource
  • Biotechnology and pharmaceutical companiesSource

Customer concentration

As of the fiscal year ended December 31, 2025, the company did not disclose specific customer concentration percentages in its 10-K, though quarterly filings have historically noted reliance on a limited number of customers.

Suppliers, materials & equipment

  • Contract Manufacturing — The company relies on third-party contract manufacturers for the production of its instruments and components; specific supplier names are not disclosed.Source

Strengths

  • Proprietary Proteograph technology platformSource
  • Growing installed base and product innovation pipelineSource

Risks

  • Dependence on third-party manufacturers and suppliersSource
  • History of operating losses and potential need for additional capitalSource

Wall Street Score

Overall investment score · Quality, value, risk and opportunity

32

Poor

PoorElite

View category scores →

Company Quality

How good is the actual business—regardless of today’s stock price?

40

Weak

Financial Strength

46

Business Quality / Moat

56

Management

40

Growth Quality

0

Risk / Durability

38

Weak Company · Expensive Stock

Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.

Opportunity

Opportunity Score · How does the current price compare with estimated value?

20

Avoid

Based on current valuation, company quality, recent trends, and available market signals.

View score details →

Model Outlook

12-month model · What does the model think happens next?

34/100

Building Historical Record

Model Score 34/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.

Probability unavailable — the model has not produced a calibrated probability yet.

Click for full breakdown →

WSS View

The quick read

The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.

At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.

The model outlook is currently cautious.

What we like
  • •Recent buyback activity is present
What to watch
  • •M&A headline · Aug 13, 2026
  • •Valuation is a weaker part of the current profile
  • •Revenue fundamentals are weak

Company-specific research

Questions worth answering for SEER

Research inputs 100% complete

These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.

  • •What is driving SEER's revenue decline, and does the latest company filing suggest the weakness is temporary or structural?
  • •How long can SEER fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • •Does SEER's balance between cash and debt leave enough flexibility if business conditions weaken?
  • •What specifically needs to improve for SEER to reach sustainable profitability?
  • •What future growth or profitability would be needed to justify SEER's current valuation?
M&A headline · Aug 13, 2026
Business analysis: 16 days ago · Fresh

Essential Investment Snapshot

Wall Street Score

32

0–100 · Poor

Opportunity Score

20

0–100 · Poor

Market Cap

$113.0M

P/E Ratio

-1.7

EPS

$-1.22

52-Week High

$2.41

52-Week Low

$1.55

Beta

1.47

Analyst Target

$4.00

Shares Outstanding

57.4M

Total Revenue

$13.8M

Total Debt

$22.4M

Dividend

No current dividend

View dividend history

Liquidation Value / Share

$3.93

Estimated net asset value per share

Momentum & Volatility Signals

Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.

0–100 market signals
Momentum
37/ 100
-4 pts / 5d

Weakening momentum

5D +1.5% · 20D -9.1% · RSI 28 · Price vs 20D avg -3.8%
Volatility
32/ 100
-17 pts / 5d

Low movement

20D realized vol 36.0% · 60D 33.6% · Acceleration 1.07x
Momentum = Where is it going?

A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.

Volatility = How violently is it moving?

A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.

Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.

Notices for SEER

Detected from reported data — verify before acting.

Historical repurchase activity

Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.

M&A headline · Aug 13, 2026

Radoff-JEC Group Calls on Seer, Inc.'s Board of Directors to Publicly Acknowledge That the Company Needs to Be Taken Private and Disclose Timeline for Evaluating Latest Acquisition Offers — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.

Business Wire

Community Sentiment

0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)

No personal call yet on SEER.

Potential upside factors

  • +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
  • +Proprietary Proteograph technology platform.
  • +Growing installed base and product innovation pipeline.

Potential downside factors

  • −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
  • −Dependence on third-party manufacturers and suppliers.
  • −History of operating losses and potential need for additional capital.
  • −Negative free cash flow may increase the need for outside financing and dilution.

These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.

Create a free account to make a call.

Scores

Click any score for full breakdown
Wall Street Score
Weak32/ 100
Weak (0–50)Fair (51–71)Strong (72+)

Poor

32

Tap for breakdown →

Fair

66

Debt Cost—
Debt Reduction YoY8.9%
Debt / Equity0.09x

Tap for breakdown →

Poor

4

Revenue YoY-14.1%
Revenue CAGR3.0%
Net Margin-490.7%

Tap for breakdown →

Fair

55

Asset Growth YoY-19.2%
Liquidation/Share$3.93
Net Assets/MCap2.09x

Tap for breakdown →

Poor

33

Earnings Yield-60.6%
Buyback Yield4.9%
Debt Cost—

Tap for breakdown →

Weak

40

ROIC-35.1%
ROE-30.1%
ROA-26.5%

Tap for breakdown →

Fair

56

EPS Growth—
FCF/Share Growth—
Rev/Share Growth41.1%

Tap for breakdown →

Poor

0

Intrinsic Value—
Value Reference—
MOS—

Tap for breakdown →

Weak

40

Revenue4
Moat56
Valuation0

Tap for breakdown →

Poor

0

MOS %—
Value Reference—
Deep Discount Reference—

Tap for breakdown →

Poor

26

Interest Coverage—
ROIC-35.1%
FCF Yield-41.2%

Tap for breakdown →

Poor

31

Financial26
Valuation0
Debt66

Tap for breakdown →

Fair

60

Survival Years4.0 yrs
Current Ratio12.84x
FCF Margin-286.9%

Tap for breakdown →

Was this stock page easy to understand?

One click helps us improve the research experience. This is not tied to an investment decision.

Score Changes

3 historical score records available

Previous Score

31

Oct 1, 2026

Change

+0.2

points

Current Score

32

Oct 19, 2026

Category Changes

Revenue+0.1
Debt0
Assets0
Capital+3.0
Management0
Moat0
Valuation0
Buffett0

SEER increased 0.2 points because Capital improved by 3 points.

Positive Contributors

  • + Capital improved by 3 points

Projected Score

Projected Score

24

Projected Change

-7.9 points

Preliminary comparable-period financial changes suggest decline of approximately 7.9 points. This is a projected estimate, not the official WallStreetScore.

Price vs. Value

Valuation unavailable

Current Price

$2.04

Model Intrinsic Value

—

Difference

—

Margin of Safety

—

Value Reference: —
Deep Discount Reference: —

Intrinsic value is not currently available for this stock, so valuation can't be calculated.

Financial Charts

Revenue

20182019202020212022202320242025$0$5M$9M$14M$18M

Additional Metrics

Operating Cash Flow

20182019202020212022202320242025-$80M-$60M-$40M-$20M$0

Total Debt

20182019202020212022202320242025$0$8M$15M$23M$30M

Total Assets

20182019202020212022202320242025$0$150M$300M$450M$600M

Net Margin %

No data
Monetary values in USD. Share counts in raw units.

Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.

Line ItemTTM20252024202320222021202020192018
Revenue$13.8M$16.1M$13.9M$15.2M····················
Cost of Revenue$7.4M$8.1M$7.1M$13.7M····················
Gross Profit$6.4M$8.0M$6.8M$1.4M····················
Research & Development$37.6M$43.9M$50.6M$47.4M····················
SG&A Expenses$40.1M$42.6M$56.6M$59.0M····················
Operating Expenses$77.2M$86.0M$106.9M$106.4M····················
EBITDA-$62.7M-$71.9M-$80.3M-$80.7M····················
Operating Income-$70.8M-$78.0M-$100.1M-$104.9M····················
Interest Expense$0.00$0.00$0.00$0.00····················
Income Before Tax-$67.9M-$73.4M-$86.5M-$86.3M····················
Income Tax Expense$71K$201K$98K$0.00····················
Net Income-$68.0M-$73.6M-$86.6M-$86.3M····················
Basic EPS$-1.22$-1.28$-1.39$-1.35····················
Basic Shares55.16M57.45M62.35M63.85M····················
Diluted Shares55.16M57.45M62.35M63.85M····················
Upgrade to Premium for up to 10 annual periods, where available.
Upgrade to Premium

Earnings Summary

Estimated earnings date:Nov 5, 2026
Estimated EPS: -$0.26Estimated revenue: $4.2M
Jun 30, 2026Q2FY2026

Revenue

$3.1M

Estimate unavailable.

Revenue Beat/Miss

Not available (no estimate stored)

EPS

-$0.31

Estimate unavailable.

EPS Beat/Miss

Not available (no estimate stored)

Debt Change

-9.8%

Cash Change

-31.3%

Margin Change

-50.8 pp

Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.

Financial Changes Since Prior Period

What Improved

  • Debt reduced

What Weakened

  • Margins contracted
  • Cash position declined

Potential Score Impact

Positive indicators included debt levels. Pressure indicators included revenue growth, EPS growth, cash levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.

Stored Earnings Analysis

Revenue declined 21.1%. EPS declined 6.1%. Cash declined 31.3%. Total debt declined 9.8%. Net income margin declined by 50.8 percentage points.

Earnings-Call Transcript

Earnings-call transcript analysis is not currently available.

These results may influence future scores when the next evaluation is completed.

Upgrade to Premium to unlock all earnings history.View plans
Earnings data: 121 days ago · Stale

Insider Activity

Guru / Smart Money

Guru Score

Smart Money

Number of Gurus

Total Guru Value

Avg Portfolio Weight

Largest Holder

Largest Holder %

New Positions

Increased Positions

Reduced Positions

Exited Positions

Net Guru Sentiment

Short Interest

Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.

Dividend History

Dividend data is not available yet. Missing data does not mean this company pays no dividend.

Conservative Projected Values

3 Years

$———.——

Premium

5 Years

$———.——

Premium

10 Years

$———.——

Premium

Conservative Projection Rate

——%

Premium

Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.

Conservative Projected Values

Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.

Start 7-Day Free Trial

Historical Outperformance Record

Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.

Start 7-Day Free Trial

Historical Trends

3 historical records
Jul 24, 26Oct 1, 26Oct 19, 260255075100

Historical Score Chart

3 of 3 records shown

Wall Street Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Debt Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Revenue Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Asset Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Capital Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Management Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Moat Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Valuation Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Buffett Score

Jul 24, 26Oct 1, 26Oct 19, 260255075100

Intrinsic Value

No data

Value Reference

No data

Margin of Safety %

No data

Related Companies

Biotechnology

AUPH

Aurinia Pharmaceuticals Inc.

84Strong
$16.74View

CGEN

Compugen Ltd.

76Strong
$1.94View

ACAD

Acadia Pharmaceuticals Inc.

73Strong
$20.44View

ORMP

Oramed Pharmaceuticals Inc.

72Strong
$4.07View

HRMY

Harmony Biosciences Holdings, Inc.

71Strong
$36.03View

CPRX

Catalyst Pharmaceuticals, Inc.

69Fair
$31.49View

News

Rumor Mill · SEER

Corporate developments & opportunities

Explore market →

No reviewed developments match this filter.

Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.

Related Stock Research

Continue researching this company with related Wall Street Score rankings and investing guides.

Highest Wall Street Score stocksStocks under $10Best growth stocksBest healthcare stocksHow Wall Street Score worksHow to analyze a stockUnderstanding financial health

Score Alerts

Premium unlocks alerts when a score rises, falls, or reaches your target price.

Start 7-Day Free Trial

Portfolio Score

Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.

Start 7-Day Free Trial